Survival Period and Life Quality of Patients with EGFR Mutation Advanced Non-small Cell Lung Cancer by Erlotinib Combined with Radiotherapy

  • Yujuan Ma
Keywords: Erlotinib; radiotherapy; EGFR mutation advanced non-small cell lung cancer; quality of life; survival period

Abstract

Erlotinib combined with radiotherapy in the study of survival and quality of life in patients with EGFR mutation advanced non-small cell lung cancer. Survival period of the patients in the treatment group was significantly better than that in the control group (P < 0.05), the difference was statistically significant; the therapeutic effect of the patients in the treatment group was significantly better than that in the control group (P < 0.05), the difference was statistically significant; after treatment, the incidence of side effects in the treatment group was 20.00%, and that in the control group was 56.67%, and the situation in the treatment group was significantly better than that in the control group Before treatment, there was no significant difference between the two groups in mental and psychological aspects, physical function, relationship with others, and overall subjective feeling scores (P > 0.05). After the treatment, the scores of mental and psychological aspects, physical function, relationship with others, and overall subjective feeling of the two groups were significantly higher than those before the treatment (P<0.05). Conclusion: radiotherapy combined with erlotinib is an effective treatment for advanced non-small cell lung cancer, which can alleviate symptoms, improve quality of life and prolong survival period. It is worth promoting in clinical treatment.

Published
2020-03-01